Clinical guidelines developed over the past two decades, such as those presented by the National Comprehensive Cancer Network (NCCN), recommend additional breast cancer screening and consideration of contralateral prophylactic mastectomy (CPM) for breast cancer patients with BRCA1 and BRCA2 mutations to address the risk of developing a second primary cancer. This evidence concerns the gene BRCA2 and cancer.